Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia

Szereday, László; Nagy, Dávid U.; Csiszar, Beata; Kevey, Dora Kinga; Feik, Timoteus; Meggyes, Mátyás

doi:10.3390/biomedicines9111608

Cited by 8 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, it was found that the proportion of Tight + CD8 + T to CD8 + in the peripheral blood of NP women was approximately 20%‐30% 98 . Expression of CD226, CD112, and CD155 was detected in T cells, NK cells, and monocyte subsets in PBMC of the NP group 99 …”

Section: Next Generation Of Inhibitory Immune Checkpoint Moleculesmentioning

confidence: 93%

“…99,101 Decreased CD226 expression and increased CD112 and CD155 surface expression were found in all T cell, NK cell, and monocyte subpopulations in women diagnosed with PE compared to the healthy group. 99 Blocking Tigit (PxxP, two in CD28 and one in CTLA-4). 103 Although it lacks classic ITIM or ITSM motifs in the cytoplasmic domain, the protein sequence contains potential protein kinase C binding sites and a proline-rich motif, which may function as a platform for interaction with other complexes (Table 1).…”

Section: Tigit Signaling In Normal Pregnancy and Pregnancy Complicationsmentioning

confidence: 93%

“…Recent studies have shown that the proportion of Tigit + CD4 + , Tigit + CD8 + T cells in the peripheral blood of PE patients is significantly decreased compared to controls 99,101 . Decreased CD226 expression and increased CD112 and CD155 surface expression were found in all T cell, NK cell, and monocyte subpopulations in women diagnosed with PE compared to the healthy group 99 . Blocking Tigit and CD155 increase inflammatory cytokines and decrease anti‐inflammatory cytokines, demonstrating the potential therapeutic value of the Tigit/CD155 pathway in PE treatment.…”

Section: Next Generation Of Inhibitory Immune Checkpoint Moleculesmentioning

confidence: 94%

“…98 Expression of CD226, CD112, and CD155 was detected in T cells, NK cells, and monocyte subsets in PBMC of the NP group. 99…”

Section: Expression Pattern Of Tigit and Its Ligands During Pregnancymentioning

confidence: 99%

See 3 more Smart Citations

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

Zhao

Muyayalo

Luo

et al. 2022

Immunological Reviews

View full text Add to dashboard Cite

Successful pregnancy is a unique situation requires the maternal immune system to recognize and tolerate a semi‐identical fetus and allow normal invasion of trophoblast cells. Although efforts have been made, the deep mechanisms of the maternal‐fetal crosstalk have not yet been fully deciphered. Immune checkpoint molecules (ICMs) are a group of negative modulators of the immune response that avoid immune damage. They have been extensively studied in the fields of oncology and transplantation, while the latest evidence suggests that they are closely associated with pregnancy outcomes via multiple inhibitory mechanisms. Although studies have mostly demonstrated the regulatory role of the well‐known PD‐1, CTLA‐4 at the maternal‐fetal interface, what is unique about the newly discovered multiple ICMs remains a mystery. Here, we review the latest knowledge on ICMs, focusing on the first generation of checkpoints (PD‐1, CTLA‐4) and the next generation (Tim‐3, Tigit, Lag‐3, VISTA) highlighting their immunoregulatory roles in maternal‐fetal tolerance and decidual vascular remodeling, and their involvement in pathological pregnancies. The content covers three aspects: the characteristics they possess, the dynamic expression profile of their expression at the maternal‐fetal interface, and their involvement in pathological pregnancy. In immunotherapy strategies for pregnancy complications, upregulation of immune checkpoints may play a role. Meanwhile, the impact on pregnancy outcomes when using ICMs in clinical cancer treatment during pregnancy is a topic worth exploring. These may serve as a guide for future basic research and clinical applications of maternal‐fetal immunity.

show abstract

Section: Next Generation Of Inhibitory Immune Checkpoint Moleculesmentioning

confidence: 93%

Section: Tigit Signaling In Normal Pregnancy and Pregnancy Complicationsmentioning

confidence: 93%

Section: Next Generation Of Inhibitory Immune Checkpoint Moleculesmentioning

confidence: 94%

“…98 Expression of CD226, CD112, and CD155 was detected in T cells, NK cells, and monocyte subsets in PBMC of the NP group. 99…”

Section: Expression Pattern Of Tigit and Its Ligands During Pregnancymentioning

confidence: 99%

See 2 more Smart Citations

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

Zhao

Muyayalo

Luo

et al. 2022

Immunological Reviews

View full text Add to dashboard Cite

show abstract

“…We did not detect any significant difference between the sCD226 levels or during the regression analyses between the surface or the relative expression of CD226. It is possible that the CD226 molecule shed from the surface of NKT cells does not stay too long in circulation but interacts with the increased amount of CD112 and CD155 ligands expressed by the monocytes, NK and T cell subsets [ 52 ]. This interaction can block these ligands from connecting with surface TIGIT or CD226 receptors.…”

Section: Discussionmentioning

confidence: 99%

CD8 and CD4 Positive NKT Subpopulations and Immune-Checkpoint Pathways in Early-Onset Preeclampsia and Healthy Pregnancy

Meggyes

Feik

Nagy

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Although many studies have investigated the clinical aspect of early-onset preeclampsia, our knowledge about the immunological consequences of improper placenta development is scarce. The maternal immunotolerance against the fetus is greatly influenced by the Th1 predominance developed by the mother’s immune system. Thirty-two early-onset preeclamptic and fifty-one healthy pregnant women with appropriately matched gestational age were involved in our study. Mononuclear cells were separated from peripheral venous blood and the frequency of CD8⁺, CD4⁺, double positive (DP), and double negative (DN) NKT cell subpopulations was determined using multicolor flow cytometry. Following the characterization, the expression levels of different immune checkpoint receptors and ligands were also defined. Soluble CD226 levels were quantified by ELISA. Novel and significant differences were revealed among the ratios of the investigated NKT subsets and in the expression patterns of PD-1, LAG-3, TIGIT and CD226 receptors. Further differences were determined in the expression of CD112, PD-1, LAG-3 and CD226 MFI values between the early-onset preeclamptic and the healthy pregnant groups. Our results suggest that the investigated NKT subpopulations act differently in the altered immune condition characteristic of early-onset preeclampsia and indicate that the different subsets may contribute to the compensation or maintenance of Th1 predominance.

show abstract

Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients

Li,

Liu,

Duan

2024

BMC Immunol

View full text Add to dashboard Cite

Background Imbalanced immune responses are involved in developing preeclampsia (PE). We wish to explore the expression and potential changes of immune checkpoint molecules TIGIT, CD226 and CD155 in PE patients. Methods The expression of the immune checkpoint molecules TIGIT, CD226 and CD155 in different lymphocyte subpopulations was determined by flow cytometry in 24 patients with PE and compared to 24 healthy pregnant women of the same gestational age as the controls.Serum CD155 was detected by ELISA in the patients with PE compared to controls. Results The percentages of CD4+ and CD8+ T lymphocytes in the peripheral blood of PE patients were not significantly different from those of the controls, whereas the regulatory T cells (Tregs) in PE patients were significantly lower than those in controls (6.43 ± 1.77% vs. 7.48 ± 1.71%, P = 0.0420). The expression of TIGIT and CD226 showed different percentages on CD4+ T cells, CD8+ T cells and Treg cells. However, the difference in the percentages of TIGIT, CD226 on these T cells between the two groups was not statistically significant. The level of CD155 in peripheral serum of PE patients was 6.64 ± 1.79 ng/ml, which was not significantly different from that in the control group 5.61 ± 1.77 ng/ml, P = 0.0505. The present results demonstrate that TIGIT, CD226 and CD155 are not present at altered immune conditions in the peripheral blood of patients with PE, compared with normal pregnant women. Conclusion The immune checkpoint molecules TIGIT, CD226 and CD155 are not abnormally expressed in PE patients.

show abstract

Examination of the TIGIT, CD226, CD112, and CD155 Immune Checkpoint Molecules in Peripheral Blood Mononuclear Cells in Women Diagnosed with Early-Onset Preeclampsia

Cited by 8 publications

References 45 publications

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

Next generation of immune checkpoint molecules in maternal‐fetal immunity*

CD8 and CD4 Positive NKT Subpopulations and Immune-Checkpoint Pathways in Early-Onset Preeclampsia and Healthy Pregnancy

Expression of the immune checkpoint molecules CD226 and TIGIT in preeclampsia patients

Contact Info

Product

Resources

About